Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company dedicated to cancer prevention, particularly focusing on patients with gastroesophageal reflux disease (GERD). GERD, commonly known as chronic heartburn or acid reflux, places millions at risk of developing esophageal precancer and the highly lethal esophageal adenocarcinoma. Lucid's groundbreaking products, EsoCheck and EsoGuard, are at the forefront of early detection and prevention.
EsoGuard is a bisulfite-converted Next Generation Sequencing (NGS) DNA assay performed on surface esophageal cells collected with the EsoCheck device. This test quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), detecting esophageal precancer and cancer with over 90% sensitivity and specificity. EsoCheck is an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device. This device can sample surface esophageal cells in less than five minutes, providing an effective, non-invasive alternative to costly and invasive endoscopy.
Lucid has shown substantial progress, including solid revenue growth on stable test volumes. Their revenue cycle management processes are improving, and the CYFT program targeting specific groups like firefighters is thriving. Their direct contracting initiative is also accelerating, with near-term prospects for delivering contracts, testing, and revenue.
Recently, Lucid announced a partnership with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. Public service videos run on Nasdaq's billboard in Times Square, spreading awareness about the link between heartburn and esophageal cancer.
Lucid's peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored study confirmed the high sensitivity and specificity of the EsoGuard test. This significant milestone supports their goal of widespread screening and early detection, moving towards Medicare coverage.
Lucid continues to advance its operations and strategies, recently closing a $30 million preferred stock financing to support their growth. They are on track to achieve key milestones, including expanded private and public coverage and direct contracting. Lucid's clinical evidence base for EsoGuard is robust, further enhancing their line of sight to Medicare coverage.
For more information, visit www.luciddx.com and their parent company PAVmed at www.pavmed.com.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announces the enrollment of the first patient in a Department of Defense-funded study at the Cleveland VA. The study investigates the effectiveness of the EsoGuard Esophageal DNA Test for early detection of esophageal precancer in GERD patients. EsoGuard, shown to be 90% sensitive and specific, aims to improve screening efficiency and reduce unnecessary endoscopies. The study will enroll up to 100 patients and compare traditional endoscopy with EsoGuard testing, assessing its impact on screening rates and cost-effectiveness within the VA system.
Lucid Diagnostics has launched Lucid Test Centers in Seattle, Portland, and Boise, offering a non-invasive test to detect esophageal precancer for patients with chronic heartburn. These centers utilize the EsoCheck device to collect surface esophageal cells for the EsoGuard DNA test, aiming to prevent esophageal cancer through early detection. The rollout reflects an expansion of their EsoGuard commercialization strategy, building on the success of existing centers.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces successful implantation of its PortIO Intraosseous Infusion System in three patients in Barranquilla, Colombia. This marks the first human use of the device in a first-in-human clinical study approved for up to 40 patients. All implantations were successful, with no complications reported. The device aims to provide maintenance-free vascular access, addressing issues associated with existing devices that require regular maintenance and can lead to serious complications. The addressable market for PortIO is estimated at over $500 million.
PAVmed Inc. (PAVM, PAVMZ) has scheduled a business update conference call for March 29, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company’s growth strategy and financial results for Q4 2021. PAVmed operates in medical devices and diagnostics, with major products like EsoGuard® and EsoCheck® for early esophageal cancer detection. The call will also provide insights on upcoming milestones and market strategies. For live access, listeners may dial designated numbers or visit the company’s investor relations page.
Lucid Diagnostics Inc. (Nasdaq: LUCD) will host a business update conference call on March 28, 2022, at 4:30 PM EDT, featuring CEO Lishan Aklog and CFO Dennis McGrath discussing growth strategies and financial results for Q4 2021. Lucid focuses on preventing esophageal cancer through its EsoGuard® test for patients with gastroesophageal disease (GERD). The company is awaiting regulatory approval for its diagnostic products, which are crucial for its future operations and potential market acceptance.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced participation at the LSI ’22 Emerging Medtech Summit on March 15-18, 2022. Chairman and CEO Dr. Lishan Aklog will present on March 17 at 3:15 p.m. PT, focusing on cancer prevention through their EsoGuard® Esophageal DNA Test, specifically for patients at risk of esophageal cancer due to GERD. Lucid, a subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), aims to enhance early detection methods with innovative diagnostics. The company is also developing a network of Lucid Test Centers for accessible testing.
Lucid Diagnostics Inc. (NASDAQ: LUCD) has launched a new subsidiary, LucidDx Labs, which now operates its own CLIA-certified laboratory in Lake Forest, CA, for conducting the EsoGuard® Esophageal DNA Test. This milestone is critical for simplifying billing processes and creating a scalable infrastructure for the growing demand for early detection of esophageal cancer. EsoGuard's effectiveness is supported by a study demonstrating over 90% sensitivity and specificity. LucidDx Labs will continue collaborating with ResearchDx for management support, further solidifying Lucid's commitment to cancer prevention.
Lucid Diagnostics Inc. (Nasdaq: LUCD) will have Dr. Lishan Aklog, Chairman and CEO, speak at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference on February 17, 2022, at 8:00 AM EST. Lucid, a cancer prevention diagnostics company, is focused on patients with gastroesophageal disease (GERD) who are at risk for esophageal precancer. Their EsoGuard® Esophageal DNA Test is the first widely available screening tool for early detection of esophageal precancer. Lucid aims to build Lucid Test Centers for the EsoCheck procedure.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) and its subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) have established a full-time investor relations team. Adrian K. Miller has been appointed Vice President, focusing on institutional investors, while D.A. Wallace takes on the role of Director for retail relations. This move aims to enhance communication with shareholders during a rapid growth phase. Both Miller and Wallace bring extensive experience in investor relations, indicating a strategic effort to improve transparency and investor engagement.
Lucid Diagnostics Inc. (Nasdaq: LUCD) will have Chairman and CEO Lishan Aklog speak at the 24th Annual Needham Virtual Growth Conference on January 11, 2022, at 11:30 AM EST. The discussion will focus on Lucid's cancer prevention diagnostic solutions, particularly the EsoGuard® test, designed for GERD patients at risk for esophageal cancer. This test, along with the EsoCheck® device, is crucial for early detection and has received FDA Breakthrough Device designation. The event can be accessed via Lucid's Investor Relations website.
FAQ
What is the current stock price of Lucid Diagnostics (LUCD)?
What is the market cap of Lucid Diagnostics (LUCD)?
What is Lucid Diagnostics Inc.?
What are EsoCheck and EsoGuard?
Why are GERD patients at risk?
How does EsoGuard work?
What recent achievements has Lucid Diagnostics announced?
What partnerships has Lucid Diagnostics formed?
What are the financial highlights for Lucid Diagnostics?
What is the significance of the NCI-sponsored study?
How does Lucid's technology compare to traditional methods?
What are Lucid's future plans?
